All In Biotech

Drug Trial Radar · NCT03654274

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain

Last checked: Nov 20, 2026Latest source record: Aug 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

802

Actual

Start

May 22, 2018

Primary completion

Dec 16, 2021

Study completion Jan 31, 2023

Sponsor

Lead sponsor
Myovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Aug 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 51 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term efficacy and safety of relugolix 40 milligram (mg) once daily co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) for up to 104 weeks on endometriosis-associated pain in participants who previously completed a 24-week treatment period in one of the parent studies (MVT-601-3101 or MVT-601-3102).

Conditions

  • Endometriosis

Interventions

  • RelugolixDrug

    Relugolix 40-mg tablet administered orally once daily

  • Estradiol/norethindrone acetateDrug

    Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 52Time frame: Week 52
  2. Percentage Of Participants Who Meet The NMPP Responder Criteria At Week 52Time frame: Week 52
  3. Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 104Time frame: Week 104
  4. Percentage Of Participants Who Meet The NMPP Responder Criteria At Week 104Time frame: Week 104

Locations

169 sites in 20 countries. Site status is shown where the registry gives one.

  • Andalusia

    Andalusia, Alabama

  • Scottsdale

    Scottsdale, Arizona

  • Tucson

    Tucson, Arizona

  • Tuscon

    Tucson, Arizona

  • Canoga Park

    Canoga Park, California

  • Los Angeles

    Los Angeles, California

  • San Diego

    San Diego, California

  • Greenwood Village

    Greenwood Village, Colorado

  • Washington

    Washington D.C., District of Columbia

  • Aventura

    Aventura, Florida

  • Fort Myers

    Fort Myers, Florida

  • Hialeah

    Hialeah, Florida

  • Hialeah

    Hialeah, Florida

  • Margate

    Margate, Florida

  • Miami

    Miami, Florida

  • Miami

    Miami, Florida

  • Sarasota

    Sarasota, Florida

  • Tampa

    Tampa, Florida

  • Atlanta

    Atlanta, Georgia

  • Atlanta

    Atlanta, Georgia

  • Augusta

    Augusta, Georgia

  • Norcross

    Norcross, Georgia

  • Idaho Falls

    Idaho Falls, Idaho

  • Oakbrook

    Oakbrook Terrace, Illinois

  • Park Ridge

    Park Ridge, Illinois

  • Shawnee

    Shawnee Mission, Kansas

  • Marrero

    Marrero, Louisiana

  • Towson

    Towson, Maryland

  • Saginaw

    Saginaw, Michigan

  • Jefferson City

    Jefferson City, Missouri

  • St. Louis

    St Louis, Missouri

  • Omaha

    Omaha, Nebraska

  • Las Vegas

    Las Vegas, Nevada

  • Durham

    Durham, North Carolina

  • New Bern

    New Bern, North Carolina

  • Winston Salem

    Winston-Salem, North Carolina

  • Akron

    Akron, Ohio

  • Columbus

    Columbus, Ohio

  • Englewood

    Englewood, Ohio

  • Hershey

    Hershey, Pennsylvania

Showing 40 of 169 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.